These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 32081779)

  • 41. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
    Zhai L; Luo C; Gao H; Du S; Shi J; Wang F
    Int J Nanomedicine; 2021; 16():3185-3199. PubMed ID: 34007173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.
    Wi TI; Won JE; Lee CM; Lee JW; Kang TH; Shin BC; Han HD; Park YM
    Int J Nanomedicine; 2020; 15():8427-8436. PubMed ID: 33149585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
    Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
    Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer.
    Zhang L; Zhang S; Jiang M; Lu L; Ding Y; Ma N; Zhao Y; Xuchen S; Zhang N
    Int J Nanomedicine; 2021; 16():5531-5550. PubMed ID: 34429598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
    de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. pH/redox dual-responsive amphiphilic zwitterionic polymers with a precisely controlled structure as anti-cancer drug carriers.
    Wu Z; Gan Z; Chen B; Chen F; Cao J; Luo X
    Biomater Sci; 2019 Aug; 7(8):3190-3203. PubMed ID: 31145392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment.
    Li M; Li Z; Yang Y; Wang Z; Yang Z; Li B; Xie X; Song J; Zhang H; Li Y; Gao G; Yang J; Mei X; Gong W
    Pharm Res; 2016 Aug; 33(8):1881-98. PubMed ID: 27075873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
    Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
    J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
    Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
    Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
    Haque ST; Islam RA; Gan SH; Chowdhury EH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.